Literature DB >> 19945913

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Katharine Bushby1, Richard Finkel, David J Birnkrant, Laura E Case, Paula R Clemens, Linda Cripe, Ajay Kaul, Kathi Kinnett, Craig McDonald, Shree Pandya, James Poysky, Frederic Shapiro, Jean Tomezsko, Carolyn Constantin.   

Abstract

Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600-6000 live male births. Although guidelines are available for various aspects of DMD, comprehensive clinical care recommendations do not exist. The US Centers for Disease Control and Prevention selected 84 clinicians to develop care recommendations using the RAND Corporation-University of California Los Angeles Appropriateness Method. The DMD Care Considerations Working Group evaluated assessments and interventions used in the management of diagnostics, gastroenterology and nutrition, rehabilitation, and neuromuscular, psychosocial, cardiovascular, respiratory, orthopaedic, and surgical aspects of DMD. These recommendations, presented in two parts, are intended for the wide range of practitioners who care for individuals with DMD. They provide a framework for recognising the multisystem primary manifestations and secondary complications of DMD and for providing coordinated multidisciplinary care. In part 1 of this Review, we describe the methods used to generate the recommendations, and the overall perspective on care, pharmacological treatment, and psychosocial management. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945913     DOI: 10.1016/S1474-4422(09)70271-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  554 in total

1.  Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

Authors:  Ida Luisa Rotundo; Stefania Faraso; Elvira De Leonibus; Gerardo Nigro; Carmen Vitiello; Alessio Lancioni; Daniele Di Napoli; Sigismondo Castaldo; Vincenzo Russo; Fabio Russo; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

2.  Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Authors:  D M Escolar; A Zimmerman; T Bertorini; P R Clemens; A M Connolly; L Mesa; K Gorni; A Kornberg; H Kolski; N Kuntz; Y Nevo; C Tesi-Rocha; K Nagaraju; S Rayavarapu; L P Hache; J E Mayhew; J Florence; F Hu; A Arrieta; E Henricson; R T Leshner; J K Mah
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

3.  Gene transfer using HACs: a key step closer to ex vivo gene therapy using autologous gene-corrected cells to treat muscular dystrophy.

Authors:  Jacques P Tremblay; Robert M Frederickson
Journal:  Mol Ther       Date:  2011-12       Impact factor: 11.454

4.  Acute Myocardial Injury in a Child with Duchenne Muscular Dystrophy: Pulse Steroid Therapy?

Authors:  Eliza Cinteza; Claudiu Stoicescu; Niculina Butoianu; Mihaela Balgradean; Alin Nicolescu; Matthias Angrés
Journal:  Maedica (Bucur)       Date:  2017-09

5.  Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers.

Authors:  Alastair Khodabukus; Amulya Kaza; Jason Wang; Neel Prabhu; Richard Goldstein; Vishal S Vaidya; Nenad Bursac
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

Review 6.  Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Authors:  Michele A Scully; Valerie A Cwik; Bruce C Marshall; Emma Ciafaloni; Jodi M Wolff; Thomas S Getchius; Robert C Griggs
Journal:  Neurology       Date:  2013-02-05       Impact factor: 9.910

7.  Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS.

Authors:  Ishu Arpan; Rebecca J Willcocks; Sean C Forbes; Richard S Finkel; Donovan J Lott; William D Rooney; William T Triplett; Claudia R Senesac; Michael J Daniels; Barry J Byrne; Erika L Finanger; Barry S Russman; Dah-Jyuu Wang; Gihan I Tennekoon; Glenn A Walter; H L Sweeney; Krista Vandenborne
Journal:  Neurology       Date:  2014-08-06       Impact factor: 9.910

Review 8.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

Review 9.  Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; Mary K Colvin; Linda Cripe; Adrienne R Herron; Annie Kennedy; Kathi Kinnett; James Naprawa; Garey Noritz; James Poysky; Natalie Street; Christina J Trout; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-02       Impact factor: 44.182

10.  Is There a Delay in Diagnosis of Duchenne Muscular Dystrophy Among Preterm-Born Males?

Authors:  Aida Soim; Michael G Smith; Jennifer M Kwon; Joshua R Mann; Shiny Thomas; Emma Ciafaloni
Journal:  J Child Neurol       Date:  2018-05-15       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.